中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 12
Dec.  2020
Turn off MathJax
Article Contents

An etiological analysis of liver diseases with negative hepatotropic virus

DOI: 10.3969/j.issn.1001-5256.2020.12.019
Research funding:

 

  • Received Date: 2020-06-16
  • Published Date: 2020-12-20
  • Objective To investigate the etiology of liver diseases with negative hepatotropic virus,and to provide ideas for the clinical diagnosis and treatment of liver diseases. Methods A retrospective analysis was performed for the clinical data and liver biopsy results of 113 patients with negative hepatotropic virus who were admitted to The Affiliated Hospital of Xuzhou Medical University from July 2018 to December 2019. According to sex,they were divided into male group with 41 patients and female group with 72 patients,and according to age,they were divided into youth group with 42 patients,middle-aged group with 56 patients,and elderly group with 15 patients. The chi-square test was used for comparison of categorical data between groups. Results Among the 113 patients with negative hepatotropic virus,111( 98. 23%) were given a confirmed diagnosis,among whom 43( 38. 05%) were diagnosed with nonalcoholic fatty liver disease( NAFLD),40( 35. 40%) were diagnosed with drug-induced liver injury( DILI),16( 14. 15%) had autoimmune liver disease( AILD),8( 7. 08%) had alcoholic liver disease,3( 2. 65%) had biliary disease,and 1( 0. 88%) had diseases in other systems which involved the liver. Among the male patients,53. 49% had NAFLD,100% had ALD,and 15% had DILI,while among the female patients,85% had DILI,46. 51% had NAFLD,and 93. 75% had AILD. For DILI,there were significantly more female patients than male patients( χ2=40. 000,P < 0. 001),and for AILD,there were also significantly more female patients than male patients( χ2= 12. 250,P < 0. 001). In the youth group,NAFLD( 55. 81%),DILI( 20%),and ALD( 75%) were the main causes of disease,and DILI was the main cause in the middle-aged group and the elderly group. Among the patients with NAFLD,there were significantly more patients in the youth group than in the elderly group( χ2= 16. 333,P < 0. 001); among the patients with DILI,there were significantly more patients in the middle-aged group than in the youth group( χ2= 8. 000,P = 0. 005); among the patients with AILD,there were significantly more patients in the middle-aged group than in the youth group( χ2= 8. 333,P = 0. 004). Conclusion Most liver diseases with negative hepatotropic virus can be diagnosed by liver biopsy,and NAFLD,DILI,and AILD are the main causes. Patients with different sexes and ages have different etiologies.

     

  • loading
  • [1] SHAO PP,SUN QL,CHENG J,et al. Epidemiological and clinical characteristics analysis in 1 062 cases of elderly liver diseases[J]. Acta Univ Med Anhui,2016,51(4):541-543.(in Chinese)邵盼盼,孙秋林,程君,等.1062例老年肝病患者临床流行病学及临床特点分析[J].安徽医科大学学报,2016,51(4):541-543.
    [2] LIU XC,ZHAO T,ZHAO ZM,et al. Incidence and trends of viral hepatitis in China[J]. J Prev Med,2018,30(5):433-437.(in Chinese)刘小畅,赵婷,赵志梅,等.中国居民病毒性肝炎流行趋势分析[J].预防医学,2018,30(5):433-437.
    [3] CHEN ZJ,ZHAO YF. Ultrasound guided percutaneous biopsy in diagnosis of liver disease and its clinical application value[J]. China J Prac Med,2014,41(10):17-19.(in Chinese)陈中建,赵永福.彩超引导下经皮穿刺活检对肝脏病变的诊断及其临床应用价值[J].中国实用医刊,2014,41(10):17-19.
    [4] Fatty Liver and Alcoholic Liver Disease Group,Hepatology Branch,Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):939-946.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病组.酒精性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):939-946.
    [5] Fatty Liver and Alcoholic Liver Disease Group,Hepatology Branch,Chinese Medical Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
    [6] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志,2015,31(11):1752-1769.
    [7] Chinese Society of Rheumatology. Guidelines for diagnosis and treatment of autoimmune liver disease[J]. Chin J Rheumatol,2011,15(8):556-558.(in Chinese)中华医学会风湿病学分会.自身免疫性肝病诊断和治疗指南[J].中华风湿病学杂志,2011,15(8):556-558.
    [8] OHARA H,OKAZAKI K,TSUBOUCHI H,et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012[J].J Hepatobiliary Pancreat Sci,2012,19(5):536-542.
    [9] Chinese Society of Rheumatology. Guidelines for diagnosis and treatment of Sjogren’s syndrome[J]. Chin J Rheumatol,2010,14(11):766-768.(in Chinese)中华医学会风湿病学分会.干燥综合征诊断及治疗指南[J].中华风湿病学杂志,2010,14(11):766-768.
    [10] DING LM,WANG F,PU LS,et al. Etiology of 202 patients with abnormal liver function tests[J]. J Pract Hepatol,2019,22(6):856-859.(in Chinese)丁利敏,王飞,朴莲淑,等.202例肝功能异常患者病因分析[J].实用肝脏病杂志,2019,22(6):856-859.
    [11] RINELLA ME. Nonalcoholic fatty liver disease:A systematic review[J]. JAMA,2015,313(22):2263-2273.
    [12] DIEHL AM,DAY C. Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med,2017,377(21):2063-2072.
    [13] YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al. Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.
    [14] BYRNE CD,TARGHER G. NAFLD:A multisystem disease[J]. J Hepatol,2015,62(1 Suppl):s47-s64.
    [15] MUSSO G,GAMBINO R,CASSADER M,et al. Meta-analysis:Natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity[J]. Ann Med,2011,43(8):617-649.
    [16] MUSSO G,GAMBINO R,TABIBIAN JH,et al. Association of non-alcoholic fatty liver disease with chronic kidney disease:A systematic review and meta-analysis[J]. PLo S Med,2014,11(7):e1001680.
    [17] WILLIAMS VF,TAUBMAN SB,STAHLMAN S. Non-alcoholic fatty liver disease(NAFLD),active component,U. S. Armed Forces,2000-2017[J]. MSMR,2019,26(1):2-11.
    [18] ALLEN AM,THERNEAU TM,LARSON JJ,et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death:A 20 year-community study[J]. Hepatology,2018,67(5):1726-1736.
    [19] LEE C,KIM J,JUNG Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Cells,2019,8(10):1259.
    [20] STINE JG,LEWIS JH. Drug-induced liver injury:A summary of recent advances[J]. Expert Opin Drug Metab Toxicol,2011,7(7):875-890.
    [21] WANG PH,HE XD,CAO JZ,et al. Comparing the clinical characteristics of IgG4-related sclerosing cholangitis with primary sclerosing cholangitis[J]. Chin J Hepatobiliary Surg,2016,22(5):315-319.(in Chinese)王鹏辉,何小东,曹建中,等.原发性硬化性与IgG4相关硬化性胆管炎临床特征比较[J].中华肝胆外科杂志,2016,22(5):315-319.
    [22] YANG Y,LUO C,HUANG QL,et al. Research progress of immunoglobulin G4-related sclerosing cholangitis[J]. Med J Chin PLA,2019,44(10):881-886.(in Chinese)杨屹,罗晨,黄启林,等.IgG4相关性硬化性胆管炎研究的进展[J].解放军医学杂志,2019,44(10):881-886.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (4095) PDF downloads(73) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return